3,3′-Diindolylmethane nanoencapsulation improves its antinociceptive action: Physicochemical and behavioral studies
- 1 September 2019
- journal article
- research article
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 181, 295-304
Abstract
No abstract availableKeywords
Funding Information
- UFSM, Fundo de Amparo à Pesquisa no Rio Grande do Sul
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
This publication has 47 references indexed in Scilit:
- Attenuation of multi-targeted proliferation-linked signaling by 3,3′-diindolylmethane (DIM): From bench to clinicMutation Research - Reviews in Mutation Research, 2011
- Cyclooxygenase inhibitors: Scope of their use and development in cancer chemotherapyMedicinal Research Reviews, 2011
- Therapeutic and Toxic Effects of New NSAIDs and Related Compounds: A Review and Prospective StudyInternational Journal of Pharmacology, 2010
- 3,3′‐diindolylmethane suppresses 12‐O‐tetradecanoylphorbol‐13‐acetate‐induced inflammation and tumor promotion in mouse skin via the downregulation of inflammatory mediatorsMolecular Carcinogenesis, 2010
- Effects of indomethacin‐loaded nanocapsules in experimental models of inflammation in ratsBritish Journal of Pharmacology, 2009
- Role of interleukin-1β during pain and inflammationBrain Research Reviews, 2009
- Nociceptors Are Interleukin-1β SensorsThe Journal of Neuroscience, 2008
- Δ6-Unsaturated fatty acids in species and tissues of the PrimulaceaePhytochemistry, 1999
- Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor αBritish Journal of Pharmacology, 1997
- The formalin test in mice: dissociation between inflammatory and non-inflammatory painPain, 1987